Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Blood pressure, stroke, and coronary heart disease

Collins, R, Peto, R, MacMahon, S, Godwin, J, Qizilbash, N, Collins, R, MacMahon, S, Hebert, P, Eberlein, K.A, Taylor, J.O, Hennekens, C.H, Fiebach, N.H, Qizilbash, N, Hennekens, C.H · 1990 · The Lancet

Abstract

There are 14 unconfounded randomised trials of antihypertensive drugs (chiefly diuretics or beta-blockers): total 37,000 individuals, mean treatment duration 5 years, mean diastolic blood pressure (DBP) difference 5-6 mm Hg. In prospective observational studies, a long-term difference of 5-6 mm Hg in usual DBP is associated with about 35-40% less stroke and 20-25% less coronary heart disease (CHD). For those dying in the trials, the DBP difference had persisted only 2-3 years, yet an overview showed that vascular mortality was significantly reduced (2p less than 0.0002); non-vascular mortality appeared unchanged. Stroke was reduced by 42% SD 6 (95% confidence interval 35-50%; 289 vs 484 events, 2p less than 0.0001), suggesting that virtually all the epidemiologically expected stroke reduction appears rapidly. CHD was reduced by 14% SD 5 (95% CI 4-22%; 671 vs 771 events, 2p less than 0.01), suggesting that just over half the epidemiologically expected CHD reduction appears rapidly. Although this significant CHD reduction could well be worthwhile, its size remains indefinite for most circumstances (though beta-blockers after myocardial infarction are of substantial benefit). At present, therefore, a sufficiently high risk of stroke (perhaps because of age, blood pressure, or, in particular, history of cerebrovascular disease) may be the clearest indication for antihypertensive treatment.

Overview

Integrity signals

Registry

Crossref · 10.1016/0140-6736(90)90944-z

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 82 references

Research works printed but not linked: 11

  1. Report of the British Hypertension Society working party, 1989, Treating mild hypertension. Agreement from the large trials, Br Med J, 298, 694
  2. First report of the Early Breast Cancer Trialists Collaborative Group. Adjuvant endocrine and cytotoxic therapy in early breast cancer: a systematic overview of all available randomized trials, NCI Monograph ((in press)).
  3. Hypertension Detection and Follow-up Program Cooperative Group, 1984, Effect of stepped care on the incidence of myocardial infarction and angina pectoris, Hypertension, 6, 198
  4. Barraclough, 1973, Control of moderately raised blood pressure: report of a co-operative randomised controlled trial, Br Med J, iii, 434
  5. 1985, Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH), J Hypenens, 3, 379
  6. 1962, Arch Intern Med, 110, 126
  7. 1962, Arch Intern Med, 110, 134
  8. 1988, Randomised tnal of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction, Lancet, ii, 349
  9. Beta-Blocker Heart Attack Trial Research Group, 1982, A randomized trial of propranolol in patients with acute myocardial infarction, JAMA, 247, 1717
  10. Multicentre International Study, 1977, Supplementary report: Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade, Br Med J, ii, 419
  11. European Infarction Study Group, 1984, A secondary prevention study with slow release oxprenolol after myocardial infarction. Morbidity and mortality, Eur Heart J, 5, 189

Cited by

See all 4,491

Metadata

Authors
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., Hennekens, C. H., Fiebach, N. H., Qizilbash, N., & Hennekens, C. H.
Affiliations
  • University of Oxford (GB)
  • Brigham and Women's Hospital (US)
  • Yale University (US)
Venue
The Lancet
Publisher
Elsevier BV
Published
1990-04
Volume
335
Issue
8693
Pages
827-838
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2139480984
Cited by
4,491
References
82
Citations by year
2026: 11 · 2025: 18 · 2024: 21 · 2023: 38 · 2022: 28 · 2021: 42 · 2020: 45 · 2019: 57 · 2018: 60 · 2017: 57 · 2016: 77 · 2015: 91 · 2014: 109 · 2013: 126 · 2012: 145
FWCI
120.93
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Wellcome Trust
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
antihypertensive drugs, blood pressure, stroke, coronary artery disease, diuretics, beta-blockers, diastolic blood pressure, vascular death, myocardial infarction, cerebrovascular disease, treatment indications
MeSH terms
Antihypertensive Agents, Blood Pressure, Cause of Death, Cerebrovascular Disorders, Coronary Disease, Diastole, Diuretics, Humans, Hypertension, Myocardial Infarction, Risk Factors, Time Factors, Bias, Odds Ratio, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood pressure, stroke, and coronary heart disease. https://app.cochat.ai/papers/10.1016/0140-6736(90)90944-z
The paper
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., Hennekens, C. H., Fiebach, N. H., Qizilbash, N., & Hennekens, C. H. (1990). Blood pressure, stroke, and coronary heart disease. The Lancet. https://doi.org/10.1016/0140-6736(90)90944-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.